Johnson & Johnson Gestione

Gestione criteri di controllo 2/4

Johnson & Johnson Il CEO è Joaquin Duato, nominato in Jan2022, e ha un mandato di 2.83 anni. la retribuzione annua totale è $ 28.40M, composta da 5.6% di stipendio e 94.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.015% delle azioni della società, per un valore di $ 56.64M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5 anni e 4.9 anni.

Informazioni chiave

Joaquin Duato

Amministratore delegato

US$28.4m

Compenso totale

Percentuale dello stipendio del CEO	5.6%
Mandato del CEO	2.8yrs
Proprietà del CEO	0.02%
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	4.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joaquin Duato rispetto agli utili di Johnson & Johnson?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 29 2024	n/a	n/a	US$15b
Jun 30 2024	n/a	n/a	US$16b
Mar 31 2024	n/a	n/a	US$17b
Dec 31 2023	US$28m	US$2m	US$13b
Oct 01 2023	n/a	n/a	US$12b
Jul 02 2023	n/a	n/a	US$12b
Apr 02 2023	n/a	n/a	US$11b
Jan 01 2023	US$13m	US$1m	US$16b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$18b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Compensazione vs Mercato: La retribuzione totale di Joaquin ($USD 28.40M ) è superiore alla media delle aziende di dimensioni simili nel mercato AR ($USD 5.71M ).

Compensazione vs guadagni: La retribuzione di Joaquin è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Joaquin Duato (61 yo)

2.8yrs

Mandato

US$28,397,240

Compensazione

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% $ 56.6m
Joseph Wolk	Executive VP & CFO	6.3yrs	US$13.91m	0.0029% $ 11.0m
Peter Fasolo	Executive VP & Chief Human Resources Officer	8.6yrs	US$7.50m	0.0047% $ 17.4m
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12.8yrs	US$11.00m	0.0064% $ 24.1m
John Reed	Executive Vice President of Innovative Medicine	1.6yrs	US$20.65m	0.00061% $ 2.3m
Robert Decker	Controller & Chief Accounting Officer	4.9yrs	Nessun dato	0.00082% $ 3.1m
James Swanson	Executive VP & Chief Information Officer	5yrs	Nessun dato	0.00061% $ 2.3m
Jessica Moore	Vice President of Investor Relations	3yrs	Nessun dato	Nessun dato
Dirk Brinckman	Chief Compliance Officer	no data	Nessun dato	Nessun dato
Elizabeth Forminard	Executive VP & Chief Legal Officer	2.1yrs	Nessun dato	0.00035% $ 1.3m
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	Nessun dato	Nessun dato
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	6.3yrs	Nessun dato	0.0034% $ 12.8m

5.0yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di JNJD è considerato esperto (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joaquin Duato	CEO & Chairman	2.8yrs	US$28.40m	0.015% $ 56.6m
Anne Mulcahy	Independent Director	15.8yrs	US$410.00k	0.00034% $ 1.3m
Hubert Joly	Independent Director	4.9yrs	US$320.00k	0.00021% $ 786.2k
Marillyn Hewson	Lead Independent Director	5.6yrs	US$360.00k	0.00012% $ 449.3k
Paula Johnson	Independent Director	1.8yrs	US$352.97k	0.000010% $ 37.4k
Mark McClellan	Independent Director	11.1yrs	US$320.00k	0% $ 0
Mary Beckerle	Independent Director	9.4yrs	US$355.00k	0% $ 0
Darius Adamczyk	Independent Director	2.8yrs	US$340.00k	0.000040% $ 149.8k
Jennifer Doudna	Independent Director	6.6yrs	US$320.00k	0% $ 0
Eugene Woods	Independent Director	less than a year	US$89.15k	Nessun dato
Mark Weinberger	Independent Director	4.9yrs	US$340.00k	0% $ 0
Nadja West	Independent Director	3.9yrs	US$340.00k	0% $ 0

4.9yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di JNJD sono considerati esperti (durata media dell'incarico 4.9 anni).

Johnson & Johnson Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson Announces Executive Changes

Recent updates

Johnson & Johnson Seeks U.S. FDA Approval for Subcutaneous Induction Regimen of Tremfya (Guselkumab) inulcerative Colitis, A First for an IL-23 Inhibitor

Johnson & Johnson Announces Results from Additional Analyses of the Phase 2 DAHLIA Study Highlighting Improvement in Key Measures of Disease Activity and IgG Reduction

Johnson & Johnson Announces U.S. Food and Drug Administration Grants Nipocalimab Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-To-Severe Sjogren's Disease

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media